Welcome!

Silverlight Authors: Automic Blog, Michael Kopp, AppDynamics Blog, Kaazing Blog, Steven Mandel

News Feed Item

AtheroGenics Announces ARISE Phase III Clinical Study Results at the American College of Cardiology's 56th Annual Scientific Session

AtheroGenics Announces ARISE Phase III Clinical Study Results at the American College of Cardiology's 56th Annual Scientific Ses

NEW ORLEANS, LA -- (MARKET WIRE) -- 03/27/07 -- AtheroGenics, Inc. (NASDAQ: AGIX) today announced the presentation of its Aggressive Reduction of Inflammation Stops Events (ARISE) Phase III clinical study of lead drug candidate, AGI-1067, at the American College of Cardiology's 56th Annual Scientific Session. While AGI-1067 did not show a difference from placebo in the composite primary endpoint, the study did achieve a number of other important predefined endpoints. These endpoints included a reduction in the composite of "hard" atherosclerotic clinical endpoints, composed of cardiovascular death, myocardial infarction (heart attack) and stroke, as well as improvement in the key diabetes parameters of new onset diabetes and glycemic control.

"The highest bar in clinical research is to improve the prognosis of patients that are already receiving optimal care," said Marc A. Pfeffer, M.D., Ph.D., Professor of Medicine, Harvard Medical School; Cardiologist at Brigham and Women's Hospital and co-principal investigator for the ARISE trial. "Although the formal primary composite endpoint in ARISE was not met, we believe that the trial generated strong evidence that use of AGI-1067 will produce tangible clinical benefits for patients with coronary artery disease."

ARISE study findings include:

--  Secondary "hard" endpoint -- In a composite of "hard" atherosclerotic
    endpoints, composed of cardiovascular death, resuscitated cardiac arrest,
    myocardial infarction (heart attack) and stroke, AGI-1067 achieved a
    meaningful relative risk reduction of 19 percent (p=0.028). A subgroup
    analysis indicated that this result was consistent across important sub-
    populations such as: patients with and without diabetes, and men and women.
    Furthermore, this result was irrespective of whether patients' baseline
    cholesterol (LDL and HDL) levels were above or below target.

--  Diabetes parameters -- Patients in ARISE taking AGI-1067 were 64
    percent less likely to develop new onset diabetes (p < 0.0001). In patients
    with diabetes, AGI-1067 improved glycemic control as measured by reductions
    in HbA1c of 0.5 percent at 12 months (p < 0.0001). These patients had a
    mean baseline HbA1c of 7.2 percent.

--  Safety and tolerability -- The most common side effect seen with AGI-
    1067 was diarrhea-related; however, it did not frequently result in patient
    discontinuation (3.3 percent vs. 0.3 percent). There was a small increase
    in the number of patients with abnormal liver function tests as measured by
    changes in a combination of liver enzymes and bilirubin (0.2 percent vs.
    0.1 percent).
    

"We are pleased with the meaningful improvement of patient outcomes observed with AGI-1067 in ARISE, which should help to address the burden of cardiovascular risk that exists despite our effective contemporary treatments," said Jean-Claude Tardif, M.D., Director of Research; Professor of Medicine, Montreal Heart Institute, University of Montreal, and co-principal investigator of the ARISE trial.

"The ARISE trial has shown that AGI-1067 demonstrated considerable efficacy in a number of important therapeutic areas, including heart disease and diabetes," said Rob Scott, M.D., Executive Vice President of Research and Development and Chief Medical Officer of AtheroGenics. "We look forward to our upcoming dialog with regulatory experts to discuss the next steps in the development program for AGI-1067."

"We included a number of endpoints in ARISE to assess the impact of AGI-1067 on both cardiovascular disease and diabetes as there exists extensive scientific literature linking oxidative stress and inflammation to both of these therapeutic areas," said Russell M. Medford, M.D., Ph. D., President and Chief Executive Officer of AtheroGenics. "We are encouraged by the results of ARISE and look forward to continuing development of this important drug with the goal of improving patient care."

About ARISE

The ARISE trial is a Phase III, double-blind, placebo-controlled trial in 6,144 patients with recent acute coronary syndrome (ACS). The trial was conducted in 259 cardiac centers in the United States, United Kingdom, Canada and South Africa. The primary endpoint in the ARISE study was to compare the effect of AGI-1067 to placebo on the time to first incidence of a composite of major adverse cardiovascular events (MACE), specifically cardiovascular death, resuscitated cardiac arrest, myocardial infarction, stroke, need for coronary revascularization and admission to hospital for unstable angina. All patients in the study were well treated with the appropriate standard of care.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. In addition to AGI-1067, the Company has another clinical-stage development program studying AGI-1096, a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit http://www.atherogenics.com.

Disclosure Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve significant risks and uncertainties, including preliminary summary statements relating to the analysis of AtheroGenics' ARISE study for AGI-1067 and preliminary summary statements relating to the potential efficacy and safety profile of AGI-1067. These and other statements contained in this press release that relate to events or developments that we expect or anticipate will occur in the future are deemed to be forward-looking statements, and can be identified by words such as "believes," "intends," "expects" and similar expressions. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. AtheroGenics cautions investors not to place undue reliance on the forward-looking statements contained in this release. The preliminary results discussed in this release may not be confirmed upon full analysis of the detailed results of the ARISE study and additional information relating to the safety, efficacy or tolerability of AGI-1067, may be discovered upon further analysis of trial data. In addition, our forward-looking statements are subject to a number of factors that could cause actual outcomes to differ materially from those expressed or implied in our forward-looking statements, including that the Food and Drug Administration might not allow us to conduct further studies of the efficacy of AGI-1067 for the same or new endpoints, and, to the extent approved, additional clinical trial work may take a significant period of time to complete or require significant additional resources to complete, or that AstraZeneca could terminate its collaboration agreement with us based on the results of the clinical trial. We cannot ensure that AGI-1067 will ever be approved or be proven safe and effective for use in humans. These and other risks are discussed in AtheroGenics' Securities and Exchange Commission filings, including, but not limited to, the risks discussed in AtheroGenics' Annual Report on Form 10-K for the fiscal year ended December 31, 2006. The risk factors regarding AtheroGenics that are included under the caption "Risk Factors" in AtheroGenics' Annual Report on Form 10-K for the fiscal year ended December 31, 2006 are specifically incorporated by reference into this press release. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

AtheroGenics, Inc.
Mark P. Colonnese
Chief Financial Officer
678-336-2511
Email Contact

Media Inquiries
Jayme Maniatis/Dana Conti
Schwartz Communications, Inc.
781-684-0770 or 508-971-4015
Email Contact

Investor Inquiries
Lilian Stern
Stern Investor Relations, Inc.
212-362-1200
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

IoT & Smart Cities Stories
Digital Transformation is much more than a buzzword. The radical shift to digital mechanisms for almost every process is evident across all industries and verticals. This is often especially true in financial services, where the legacy environment is many times unable to keep up with the rapidly shifting demands of the consumer. The constant pressure to provide complete, omnichannel delivery of customer-facing solutions to meet both regulatory and customer demands is putting enormous pressure on...
SYS-CON Events announced today that IoT Global Network has been named “Media Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. The IoT Global Network is a platform where you can connect with industry experts and network across the IoT community to build the successful IoT business of the future.
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
Machine learning has taken residence at our cities' cores and now we can finally have "smart cities." Cities are a collection of buildings made to provide the structure and safety necessary for people to function, create and survive. Buildings are a pool of ever-changing performance data from large automated systems such as heating and cooling to the people that live and work within them. Through machine learning, buildings can optimize performance, reduce costs, and improve occupant comfort by ...
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time t...
CloudEXPO New York 2018, colocated with DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
DXWorldEXPO | CloudEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.
Disruption, Innovation, Artificial Intelligence and Machine Learning, Leadership and Management hear these words all day every day... lofty goals but how do we make it real? Add to that, that simply put, people don't like change. But what if we could implement and utilize these enterprise tools in a fast and "Non-Disruptive" way, enabling us to glean insights about our business, identify and reduce exposure, risk and liability, and secure business continuity?
In this Women in Technology Power Panel at 15th Cloud Expo, moderated by Anne Plese, Senior Consultant, Cloud Product Marketing at Verizon Enterprise, Esmeralda Swartz, CMO at MetraTech; Evelyn de Souza, Data Privacy and Compliance Strategy Leader at Cisco Systems; Seema Jethani, Director of Product Management at Basho Technologies; Victoria Livschitz, CEO of Qubell Inc.; Anne Hungate, Senior Director of Software Quality at DIRECTV, discussed what path they took to find their spot within the tec...
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...